- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06664788
[Prøving av enhet som ikke er godkjent eller godkjent av U.S. FDA]
The objective of this clinical investigation is to evaluate the safety and efficacy of ETHIZIA to control minimal, mild, or moderate soft tissue bleeding during open surgery when compared to SURGICEL Original in the percentage of cases achieving hemostasis at 3 minutes after product application, and without re-bleeding up to 10 minutes after application.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90033
- Keck Hospital of USC
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Washington University Barnes Jewish Hospital
-
-
New Jersey
-
Pennington, New Jersey, Forente stater, 08534
- Capital Health Medical Center - Hopewell
-
-
New York
-
New York, New York, Forente stater, 10065
- New York Presbyterian - Weill Cornell Medical Ctr
-
-
Texas
-
Tyler, Texas, Forente stater, 75701
- UT Health East Texas EMS Air 1
-
-
Utah
-
Murray, Utah, Forente stater, 84107
- Intermountain Medical Center
-
-
-
-
-
Nijmegen, Nederland, 6500HB
- UMC Radboud
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Pre-operative
- Participant is scheduled to undergo an elective open, abdominal, retroperitoneal, pelvic, thoracic (non-cardiac) or extremity surgical procedure
- Participant is willing and able to give written informed consent for the clinical investigation participation
Intra-operative
- Participant in whom the Investigator can identify and visualize a target bleeding site for which any applicable conventional means for hemostasis (e.g., suture, ligature, or cautery) are ineffective or impractical
- Target Bleeding Site is identified to originate from soft tissue, defined as organ bed, loose areolar tissue, fat, lymphatic tissue/lymph node beds, and muscle
- The choice is made to use a hemostatic agent to stop the bleeding, and there is the ability to apply pressure on the surface of the hemostatic agent to achieve hemostasis
- Participant has a Target Bleeding Site with a SBSS score of 1, 2, or 3 (e.g., reflecting minimal, mild, or moderate bleeding severities)
Exclusion Criteria:
Pre-operative
- Participant is scheduled for another planned surgery within the follow-up period and the subsequent surgery would jeopardize the ETHIZIA or SURGICEL Original application
- Participant is taking multiple antithrombotic therapies in therapeutic dosage up to the time of surgery, but allowing exclusive use of acetylsalicylic acid
- Participant has an active or suspected infection at the bleeding site
- Participant is pregnant, planning on becoming pregnant, or actively breastfeeding during the 28-day follow-up period
Intra-operative
- Target bleeding site is identified to originate from parenchymal organ tissue, cardiovascular (anastomotic or cardiovascular repair sites) tissue, or is in proximity to a foramina in bone, or areas of bony confine
- Target bleeding site is from a large defect in an artery or vein that requires vascular reconstruction with maintenance of vessel patency
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: ETHIZIA
ETHIZIA will be applied at bleeding sites that meet the inclusion criteria in participants undergoing open surgery to control soft tissue bleeding. Participants will be followed up for 28 days after surgery. |
ETHIZIA patch will be applied to bleeding site intraoperatively. |
|
Aktiv komparator: SURGICEL Original
SURGICEL Original will be applied at bleeding sites that meet the inclusion criteria in participants undergoing open surgery to control soft tissue bleeding. Participants will be followed-up for 28 days after surgery. |
SURGICEL Original will be applied to bleeding site intraoperatively. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Cases Achieving Hemostasis at Three Minutes Following Product Application And With No Rebleeding Up to 10 Minutes Following Application at The Target Bleeding Site
Tidsramme: Intraoperative (up to 10 minutes)
|
Cases achieving hemostasis at 3 minutes following product application & with no rebleeding up to 10 minutes following application at the target bleeding site (first bleeding site treated) will be determined by Surface Bleeding Severity Scale (SBSS). SBSS provides a clinically validated score for assessment of bleeding at the target site, and consists of 6 scores (0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, not immediately life-threatening, 5 = extreme, immediately life-threatening). A grade of 0 (None/Dry) on the SBSS is considered as achieving hemostasis. |
Intraoperative (up to 10 minutes)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to Hemostasis at Target Bleeding Site
Tidsramme: Intraoperative (up to 10 minutes)
|
Time to achieve hemostasis for target bleeding site up to 10 minutes will be evaluated and presented using Kaplan-Meier estimated distribution. |
Intraoperative (up to 10 minutes)
|
|
Percentage of Bleeding Sites Achieving Hemostasis at Three Minutes Following Product Application And With No Rebleeding Up to 10 Minutes Following Application at All Treated Bleeding Sites
Tidsramme: Intraoperative (up to 10 minutes)
|
Percentage of bleeding sites achieving hemostasis at 3 minutes following product application & with no rebleeding up to 10 minutes following application at all bleeding sites (additional bleeding sites treated including target bleeding site) will be determined by SBSS. SBSS provides a clinically validated score for assessment of bleeding at the target site, and consists of 6 scores (0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, not immediately life-threatening, 5 = extreme, immediately life-threatening). |
Intraoperative (up to 10 minutes)
|
|
Time to Hemostasis for All Treated Bleeding Sites
Tidsramme: Intraoperative (up to 10 minutes)
|
Time to achieve hemostasis for all treated bleeding sites for up to 10 minutes will be evaluated. |
Intraoperative (up to 10 minutes)
|
|
Median Time to Hemostasis at Target Bleeding Site
Tidsramme: Intraoperative
|
Median time to hemostasis at target bleeding site will be reported. |
Intraoperative
|
|
Median Time to Hemostasis for All Treated Bleeding Sites
Tidsramme: Intraoperative
|
Median time to hemostasis for all treated bleeding sites will be reported for both groups. |
Intraoperative
|
|
Treatment Failure for Target Bleeding Site Treated and for All Treated Bleeding Sites
Tidsramme: Intraoperative (up to 10 minutes)
|
Treatment failure is defined as no hemostasis at 10 minutes or received rescue therapy prior to 10 minutes from the application of the study product. |
Intraoperative (up to 10 minutes)
|
|
Sustained Hemostasis at All Treated Bleeding Sites
Tidsramme: Intraoperative
|
Sustained hemostasis at all treated bleeding sites will be reported. Sustained hemostasis is defined as achieving hemostasis at 3 minutes with no rebleeding up to Day 28. |
Intraoperative
|
|
Proportion of Bleeding Sites with Rebleeding After 10 Minutes
Tidsramme: Intraoperative
|
Proportion of bleeding sites with rebleeding after 10 minutes and prior to initiation of final fascia closure will be reported. Summaries will be presented for target bleeding site and for all treated bleeding sites. |
Intraoperative
|
|
Percentage of Bleeding Sites Achieving Hemostasis with ETHIZIA or SURGICEL Original
Tidsramme: At 30, 60, 120, 180, 240, 300, 360, 420, 480, 540, and 600 seconds
|
Percentage of bleeding sites achieving hemostasis with ETHIZIA or SURGICEL Original will be reported. Summaries will be presented for target bleeding site and for all treated bleeding sites. |
At 30, 60, 120, 180, 240, 300, 360, 420, 480, 540, and 600 seconds
|
|
Proportion of Bleeding Sites Requiring More Than One Application of ETHIZIA or SURGICEL Original to Achieve Hemostasis
Tidsramme: Intraoperative
|
Proportion of bleeding sites requiring more than one application of randomized product in order to achieve hemostasis will be reported. Summaries will be presented for target bleeding site and for all treated bleeding sites. |
Intraoperative
|
|
Proportion of Bleeding Sites that Require a Second Surgical Maneuver to Achieve Hemostasis
Tidsramme: Intraoperative
|
Proportion of bleeding sites that require a second surgical maneuver (for example, adjunct product, electrocautery, etcetera) as a rescue therapy to achieve hemostasis following treatment will be reported. Summaries will be presented for target bleeding site and for all treated bleeding sites. |
Intraoperative
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Ethicon Inc. Clinical Trial, Ethicon, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- BIO202401
- BIO202401 (Annen identifikator: Ethicon,Inc)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .